NCT03062826|UnknownDMC
EROSION II: OCT Guided PPCI in STEMI
A Prospective, Multi-center, Optical Coherence Tomography Guided Reperfusion Strategy in Patients With STEMI (EROSION II)
Loading search results
A Prospective, Multi-center, Optical Coherence Tomography Guided Reperfusion Strategy in Patients With STEMI (EROSION II)
Sponsor study identifier
observational
347
1 country
16
Study Start
January 11, 2017
Actual (reported)Primary Completion
February 24, 2022
Actual (reported)Study Completion
March 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This protocol describes a prospective, multi-center study intended to test the hypothesis that patients with STEMI caused by plaque rupture or plaque erosion without obstructive stenosis (diameter stenosis \<70%) can be stabilized by effective antithrombotic treatment without stent implantation, thereby avoiding both early and late complications related to percutaneous coronary intervention (PCI) with stent implantation. All the patients will be followed by intracoronary OCT and physiological assessment at 1-month and 12-month follow-up.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 11, 2017
Actual (reported)February 20, 2017
Actual (reported)February 23, 2017
Actual (reported)February 24, 2022
Actual (reported)March 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Reduction of thrombus burden assessed by OCT
The efficacy will be assessed by 50% reduction in thrombus burden by OCT at 1 month.
30 days
Major cardiovascular adverse events
1, 3, 6, 9, 12 months after PCI
Major cardiovascular adverse events
1 and 12 months after PCI
Effective flow area increase
1 and 12 months after PCI
Fractional flow reserve
1 and 12 months after PCI
Drug: dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) for at least 12 months.
Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Study population is STEMI patients who undergo primary cardiac catheterization.
Beijing Luhe Hospital
Beijing, Beijing Municipality, 101100, China
Xiamen Cardiovascular Hospital, Xiamen University
Xiamen, Fujian, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Shenzhen Sun Yat-sen Cardiovascular Hospital
Shenzhen, Guangzhou, China
Hebei General Hospital
Shijiazhuang, Hebei, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150081, China
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
Blood sample will be obtained from artery sheath or coronary artery by aspiration catheter during the PCI procedure in selected sites, and will be stored at -80°C.
Bo YU, MD, PhD
The Second Affiliated Hospital of Harbin Medical University
347 participants (actual enrollment reported by the registry).
First Submitted
February 20, 2017
First Posted
February 23, 2017
Study Start
January 11, 2017
Actual (reported)Prognostic Value of Copeptin for Infarct Size and Prognosis in Patients With ST-elevation Myocardial Infarction
Contact the study team to confirm eligibility.
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
China-Japan Union Hospital of Jilin University
Changchun, Jilin, 130000, China
The First Hospital of Jilin University
Changchun, Jilin, 130000, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Shanxi Cardiovascular Hospital
Taiyuan, Shanxi, China
The First Affiliated Hospital of Dalian Medical University
Dalian, Shenyang, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Primary Completion
February 24, 2022
Actual (reported)Study Completion
March 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
June 27, 2022
Record last verified: 2022-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: